IP Library Granted Patent US 8,034,821
Granted Patent B2
US 8,034,821 · App. 12/698,027 · Granted Oct 11, 2011

Selective serine/threonine kinase inhibitors

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,821
App. No.
12/698,027
Granted
Oct 11, 2011
Kind
B2
Abstract

Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase. Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase. Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.

Claims (38)

1. A compound having the formula (I):

in which:

R 1 is NHR a wherein R a is hydrogen or an optionally substituted aliphatic, aromatic or heterocyclic group;

R 2 is hydrogen or a group having the formula (CH 2 ) b R b wherein b is 0 or an integer from 1 to 3 and R b is an aromatic, heterocyclic or cyclical aliphatic group optionally substituted with one or more groups selected from lower alkyl, halogen, substituted alkyl, nitro, alkoxy, phenoxy, or sulfonamido;

R 3 is hydrogen or an aliphatic, aromatic, or heterocyclic group;

R 4 is an electrophilic group E;

R 5 is hydrogen, alkoxy, alkylthio, alkylamino, aryloxy, arylthio, or arylamino; and

E is —(CH 2 ) m COR′, —CO(CH 2 ) n R′, —C(O)C(O)R′, an epoxide, or an olefin attached to an electron withdrawing group, wherein m and n are independently 0 or an integer from 1 to 6, wherein R′ is independently hydrogen, halogen, amino, substituted amino, cyano, an optionally substituted aliphatic, an optionally substituted aromatic, or an optionally substituted heterocyclic group.

2. A compound according to claim 1 in which E is an epoxide or an olefin attached to an electron withdrawing group.

3. A compound according to claim 1 in which R 2 is hydrogen.

4. A compound according to claim 1 in which R 2 is a group having the formula (CH 2 ) b R b .

5. A compound according to claim 4 in which R 2 is an optionally substituted phenyl group.

6. A compound according to claim 2 in which E is an olefin attached to a nitro, cyano, sulfoxide, sulfonyl, sulfonamide, or sulfonate group.

7. A compound according to claim 1 in which E is —C(O)(CH 2 ) n R′ in which R′ is a halogen and n is 0 or an integer from 1 to 6.

8. A compound according to claim 1 in which E is —(CH 2 ) m C(O)R′ in which m is 0 or an integer from 1 to 6 and R′ is a halogen.

9. A compound according to claim 7 in which R′ is chloro.

10. A compound according to claim 7 in which R′ is fluoro.

11. A compound according to claim 1 in which E is —(CH 2 ) m COR′, —CO(CH 2 ) n R′ or —C(O)C(O)R′, wherein m and n are independently 0 or an integer from 1 to 6, wherein R′ is a substituted aliphatic, substituted aromatic, or substituted heterocyclic group, each substituted with one or more substituents from the group consisting of halo, hydroxyl, thiol, nitro, amino, substituted amino, amido, substituted amido, alkoxy, haloalkoxy, alkylenedioxy, alkyl, haloalkyl, hydroxyalkyl, and sulfonyl.

12. A compound according to claim 1 in which E is —(CH 2 ) m COR′, —CO(CH 2 ) n R′ or —C(O)C(O)R′, wherein m and n are independently 0 or an integer from 1 to 6, wherein R′ is an alkyl group independently substituted with one or more optionally substituted aryl groups.

13. A compound according to claim 12 wherein the substituted aryl groups are independently substituted with one or more of the group consisting of halo, hydroxyl, thiol, nitro, amino, substituted amino, amido, substituted amido, alkoxy, haloalkoxy, alkylenedioxy, alkyl, haloalkyl, hydroxyalkyl, and sulfonyl.

14. A compound according to claim 1 in which E is —(CH 2 ) m COR′, —CO(CH 2 ) n R′ or —C(O)C(O)R′, wherein m and n are independently 0 or an integer from 1 to 6, wherein R′ is an alkyl group independently substituted with one or more saturated or unsaturated heterocyclic groups.

15. A compound according to claim 14 wherein the one or more heterocyclic groups are independently substituted with one or more of the group consisting of halo, hydroxyl, thiol, nitro, amino, substituted amino, amido, substituted amido, alkoxy, haloalkoxy, alkylenedioxy, alkyl, haloalkyl, hydroxyalkyl, sulfonyl, optionally substituted lower alkyl, and optionally substituted lower alkoxy.

16. A compound according to claim 1 in which E is —(CH 2 ) m COR′, —CO(CH 2 ) n R′ or —C(O)C(O)R′, wherein m and n are independently 0 or an integer from 1 to 6, wherein R′ is an alkyl group independently substituted with one or more optionally substituted cycloaliphatic groups.

17. A compound according to claim 16 wherein the one or more cycloaliphatic groups are independently substituted with one or more of the group consisting of halo, hydroxyl, thiol, nitro, amino, substituted amino, amido, substituted amido, alkoxy, haloalkoxy, alkylenedioxy, alkyl, haloalkyl, hydroxyalkyl, and sulfonyl.

18. A compound according to claim 1 in which E is —(CH 2 ) m COR′, —CO(CH 2 ) n R′ or —C(O)C(O)R′, wherein m and n are independently 0 or an integer from 1 to 6, wherein R′ is an optionally substituted heterocyclic group.

19. A compound according to claim 18 wherein the R′ heterocyclic group is substituted with one or more of the group consisting of halo, hydroxyl, thiol, nitro, amino, substituted amino, amido, substituted amido, alkoxy, haloalkoxy, alkylenedioxy, alkyl, haloalkyl, hydroxyalkyl, sulfonyl, optionally substituted lower alkyl, and optionally substituted lower alkoxy.

20. A compound according to claim 1 in which E is —CH═CHC(O)OR c wherein R c is an optionally substituted aliphatic, aromatic, or heterocyclic moiety.

21. A compound according to claim 20 in which E is —CH═CH—C(O)—OCH 3 .

22. A compound according to claim 1 in which E is —C(O)CH═CH 2 .

23. A compound according to claim 1 in which R 5 is hydrogen.

24. A compound according to claim 4 in which b is 0.

25. A compound according to claim 4 in which R b is an aromatic optionally substituted with one or more groups selected from lower alkyl, halogen, substituted alkyl, nitro, alkoxy, phenoxy, or sulfonamido.

26. A compound according to claim 25 in which R b is an aromatic group substituted with lower alkyl.

27. A compound according to claim 6 in which E is an olefin attached to a cyano.

28. A compound according to claim 6 in which E is an olefin attached to a nitro.

29. A compound according to claim 8 in which R′ is chloro.

30. A compound according to claim 8 in which R′ is fluoro.

31. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 12, 2017
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044836/0664 →
Continuity (3)
Continuation 10552847
Provisional Application 60462554 · Apr 11, 2003
Related Publication 20100256171A1 · Oct 7, 2010